Invention Grant
- Patent Title: Treatment of cancers using anti-NKG2A agents
-
Application No.: US16448016Application Date: 2019-06-21
-
Publication No.: US11225519B2Publication Date: 2022-01-18
- Inventor: Pascale Andre , Mathieu Blery , Caroline Soulas , Nicolai Wagtmann
- Applicant: INNATE PHARMA
- Applicant Address: FR Marseilles
- Assignee: INNATE PHARMA
- Current Assignee: INNATE PHARMA
- Current Assignee Address: FR Marseilles
- Agency: Saliwanchik, Lloyd & Eisenschenk
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K39/00
Abstract:
The present invention relates to HLA-E as a tumor escape mechanism in head and neck cancer. The invention relates to methods for the treatment of head and neck cancer, notably HLA-E expressing head and neck squamous cell carcinoma, using antibodies that specifically bind and inhibit human NKG2A.
Public/Granted literature
- US20190322744A1 TREATMENT OF CANCERS USING ANTI-NKG2A AGENTS Public/Granted day:2019-10-24
Information query
